𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer

✍ Scribed by Hans Christian Blossey; Hans Helge Bartsch; Dietrich Kanne; Johannes Koebberling; Gerhard Arno Nagel

Publisher
Springer
Year
1982
Tongue
English
Weight
425 KB
Volume
8
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II study of high-dose medroxypro
A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer
✍ Geoffrey Falkson; HΓ¨ndrΓ© C. Falkson πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high

Pharmacokinetic and pharmacodynamic basi
Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate
✍ Hans Christian Blossey; Hans Erik Wander; Johannes Koebberling; Professor Dr. Ge πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 728 KB

Postmenopausal patients with metastatic breast cancer were treated with medroxyprogesterone acetate (MPA) (Clinovir) in dosages between 500 and 1500 mg orally per day. The relation of MPA plasma concentrations and endocrine effects were studied in a longitudinal fashion. MPA exerted suppressive effe

Mechanism of adrenal suppression by high
Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients
✍ H. Veelen; P. H. B. Willemse; D. T. Sleijfer; E. Ploeg; W. J. Sluiter; H. Dooren πŸ“‚ Article πŸ“… 1985 πŸ› Springer 🌐 English βš– 362 KB

To investigate the mechanism of adrenal suppression by high-dose MPA, we performed direct and indirect stimulation tests in postmenopausal women with disseminated breast cancer who were receiving MPA and in a postmenopausal breast cancer control group. A partial adrenal insufficiency was found durin